Guillain-Barre Syndrome (GBS) Market Analysis

Guillain-Barre Syndrome Market Analysis

To get key market trends

  Download Free Sample

Based on treatment type, the market is classified into first-line treatment and supportive treatment. The first-line treatment segment is expected to hold the largest market share and maintain dominance with a projected CAGR of 4.8%.

• The first-line treatment dominance was attributed to its widespread adoption as the primary therapeutic intervention for managing GBS.

   

• The significant market share of IVIG is anticipated, owing to the availability of diverse products such as Gamunex, Gammagard, and Privigen, alongside the expanding adoption of off-label IVIG use due to the increasing prevalence of conditions such as multifocal motor neuropathy, dermatomyositis, and others.

   

• Additionally, the substantial burden of GBS in the U.S., affecting 3,000-6,000 individuals annually according to the Centers for Disease Control and Prevention, is driving demand for effective treatments. Similarly, Assiut University's clinical trial on "Mini-pool Intravenous Immunoglobulin (MP-IVIG) in GBS," set to conclude by December 2022, is poised to introduce new products.

Based on type, the GBS market is categorized into acute inflammatory demyelinating polyneuropathy (AIDP), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), miller fisher syndrome (MFS), acute motor axonal neuropathy (AMAN), and other types. The AIDP segment is projected accounted the largest market share of 59.7% in 2023 and is expected to maintain dominance throughout the analysis period.

• AIDP represents the most common form of GBS, characterized by symmetrical weakness and demyelination of peripheral nerves. Its prominence in the market is attributed to its higher prevalence compared to other GBS variants. Also, as the primary type contends within clinical practice, AIDP drives demand for diagnostic tests, treatment modalities, and research initiatives in the GBS market.

   

Based on gender, the Guillain-Barre syndrome (GBS) market is bifurcated into male and female. The male segment accounted for the highest share and is expected to reach USD 678.7 million by 2032.

• GBS exhibited a higher prevalence in males compared to females. Factors such as genetic predispositions, hormonal influences, and environmental triggers may contribute to the higher incidence of GBS in males.

   

• Furthermore, availability of both first line treatment and supportive care along with ongoing research activities to develop innovative products will augment the market growth.

   

Based on age group, the Guillain-Barre syndrome market is classified into below 20 years, 21-40 years, 41-59 years, and 60 and above. The age segment of 41-59 years contributed the largest revenue of USD 230.6 million in 2023.

• The 41-59 years age group represented a significant portion of GBS cases, possibly due to a combination of factors such as increased susceptibility to infections, higher prevalence of autoimmune conditions, and age-related changes in the immune system. Targeting this age demographic is crucial for market stakeholders in developing tailored diagnostic and treatment solutions.

   

Based on end-user, the guillain-barre syndrome market is categorized into hospitals, clinics, rehabilitation centers, and other end-users. The hospital segment is projected to reach USD 401.4 million growing at a CAGR of 4.6% during the analysis period.

• This surge in demand can be attributed to hospitals being primary centers for GBS diagnosis, treatment, and management. With specialized medical professionals, advanced diagnostic facilities, and comprehensive care infrastructure, hospitals are pivotal in providing acute care, rehabilitation services, and long-term support to GBS patients. Such benefits associated with hospital setting will supplement the market growth.

U.S. dominated the North American Guillain-Barre syndrome market accounting for the highest market revenue of USD 305.4 million in 2023 anticipating significant growth over the analysis period.

• This dominance stems from various factors, including a growing geriatric population at higher risk of GBS, the presence of major market players, and increased awareness about GBS. According to the Centers for Disease Control and Prevention (CDC), Campylobacter jejuni infection, a common cause of GBS, particularly affects individuals over 50. Therefore, prioritizing early diagnosis and comprehensive treatment, including immunotherapy and rehabilitation services, the country fosters a supportive environment for U.S. patients anticipating the market expansion.

   

• Also, public funding for GBS-related projects, exemplified by the National Institute of Neurological Disorders and Stroke's (NINDS) funding approval for a research project, further augments regional market growth.

   

Germany exhibited a high growth potential in the European Guillain-Barre syndrome market.

• Rising focus on innovation and research, country aims to expedite the clinical trials and collaborates with pharmaceutical companies to develop new therapies and treatment protocols for GBS are few factors driving the market demand.

   

• In addition, the country’s robust network of hospitals and specialized neurological centers ensuring prompt diagnosis, multidisciplinary treatment, and rehabilitation services for individuals with GBS anticipates attracting a large patient.

   

• Further, collaborations among academic institutions, healthcare providers, and pharmaceutical firms stimulate innovation and therapeutic progress in the GBS therapeutic area, thereby propelling market expansion.

   

Japan gained traction in the GBS market anticipating substantial growth during the analysis period.

• Robust clinical research and partnerships with global companies to extend insights into GBS pathophysiology and treatment alternatives indicate significant growth prospects in the foreseeable future. Also, regulatory bodies in Japan scrutinize and authorize new GBS therapies, guaranteeing adherence to safety and efficacy criteria for patient welfare. This enables a positive awareness among the patient population which will in turn spur the country level market growth.

   

• Further, in Japan, rehabilitation services like physical and occupational therapy play a vital role in enhancing functional capabilities as part of managing GBS, thus contributing to the forecasted expansion of the market.